TBIO vs. PRPO, TLIS, AXDX, HLTH, OMIC, RPID, BMRA, BRTX, ONVO, and ADXN
Should you be buying Telesis Bio stock or one of its competitors? The main competitors of Telesis Bio include Precipio (PRPO), Talis Biomedical (TLIS), Accelerate Diagnostics (AXDX), Cue Health (HLTH), Singular Genomics Systems (OMIC), Rapid Micro Biosystems (RPID), Biomerica (BMRA), BioRestorative Therapies (BRTX), Organovo (ONVO), and Addex Therapeutics (ADXN). These companies are all part of the "medical" sector.
Telesis Bio (NASDAQ:TBIO) and Precipio (NASDAQ:PRPO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, community ranking, risk and analyst recommendations.
Precipio received 263 more outperform votes than Telesis Bio when rated by MarketBeat users. Likewise, 73.32% of users gave Precipio an outperform vote while only 52.94% of users gave Telesis Bio an outperform vote.
In the previous week, Precipio had 3 more articles in the media than Telesis Bio. MarketBeat recorded 3 mentions for Precipio and 0 mentions for Telesis Bio. Telesis Bio's average media sentiment score of 0.00 beat Precipio's score of -0.37 indicating that Telesis Bio is being referred to more favorably in the media.
Telesis Bio has a beta of 1.93, suggesting that its stock price is 93% more volatile than the S&P 500. Comparatively, Precipio has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500.
37.6% of Telesis Bio shares are held by institutional investors. Comparatively, 10.5% of Precipio shares are held by institutional investors. 24.5% of Telesis Bio shares are held by insiders. Comparatively, 10.6% of Precipio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Precipio has a consensus target price of $40.00, suggesting a potential upside of 535.93%. Given Precipio's higher probable upside, analysts plainly believe Precipio is more favorable than Telesis Bio.
Precipio has a net margin of -31.00% compared to Telesis Bio's net margin of -183.66%. Precipio's return on equity of -46.12% beat Telesis Bio's return on equity.
Precipio has lower revenue, but higher earnings than Telesis Bio. Precipio is trading at a lower price-to-earnings ratio than Telesis Bio, indicating that it is currently the more affordable of the two stocks.
Summary
Precipio beats Telesis Bio on 10 of the 16 factors compared between the two stocks.
Get Telesis Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Telesis Bio Competitors List
Related Companies and Tools
